Global Blood Therapeutics
(NASDAQ) GBT
This security has been delisted. This page is retained for historical reference.
GBT News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowGBT Financials
Key Financial Metrics (TTM)
Gross Margin
98%
Operating Margin
-1%
Net Income Margin
-2%
Return on Equity
-99%
Return on Capital
-34%
Return on Assets
-32%
Earnings Yield
N/A
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
N/A
Shares Outstanding
N/A
Volume
N/A
Short Interest
N/A
Avg. Volume
N/A
Financials (TTM)
Gross Profit
$191.43M
Operating Income
$287.15M
EBITDA
$278.53M
Operating Cash Flow
$256.81M
Capital Expenditure
$3.23M
Free Cash Flow
$260.05M
Cash & ST Invst.
$684.72M
Total Debt
$659.62M
Global Blood Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonCurrently no data to display.
Quarterly Performance
Revenue
$71.55M
+50.5%
Gross Profit
$70.14M
+49.8%
Gross Margin
98.03%
N/A
Market Cap
N/A
N/A
Market Cap/Employee
N/A
N/A
Employees
457
N/A
Net Income
$82.47M
-18.5%
EBITDA
$71.57M
-12.3%
Quarterly Fundamentals
Net Cash
$141.23M
-168.4%
Accounts Receivable
$29.77M
+52.3%
Inventory
$65.82M
+37.1%
Long Term Debt
$652.27M
+189.0%
Short Term Debt
$6.12M
+16.7%
Return on Assets
-32.27%
N/A
Return on Invested Capital
-33.73%
N/A
Free Cash Flow
$44.69M
+0.9%
Operating Cash Flow
$44.31M
+0.0%